Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Post by Jefferam1on Jan 24, 2018 10:35pm
321 Views
Post# 27429050

Antibe attending Conference

Antibe attending ConferenceSo I grew curious what this video was about and if I can dig up any more info.
From the video side, unfortuantely no luck.
However seeing where it was filmed that led me to this.
Looks like Antibe attended a Captial Event Conference
https://www.capitalevent.ca/issuer_testimonials/
There is a comment on this page to validate that.

From what I can tell, they attended the following one: CEM: ALPHANORTH CAPITAL CONFERENCE | BAHAMAS, JANUARY 12 - 14, 2018

https://www.stockpools.com/pools/cem-alphanorth-capital-conference-january-12-14-2018/my-picks

Judging by the date, I can't say there was a significant impact. But all the same it can't be a bad thing. The only slight concern is why for this timing? are they trying to raise money? Just curious here? 

I'm guessing the video was a promo for the event. Doesn't seem like the type of event to help get a partner deal with a large pharma? Regardless exposer is always good.
Anyone else has any thoughts?
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities